Mutations in KRAS and TP53 that are frequently observed in colorectal cancer have been considered to be the markers of a poor response to CRT in rectal cancer.75, 76 Duldulao et al carried out KRAS and TP53 genotyping in rectal cancer and showed that tumors with the KRAS mutation were less likely to achieve pCR than those with wild‐type KRAS (P = 0.006).77 Interestingly, in their study, no tumors with KRAS codon 13 mutations achieved pCR (P = 0.03), and these tumors also had a higher incidence of the TP53 mutation compared with tumors with other KRAS mutations (P = 0.02). This evidence concerns the gene KRAS and rectal cancer.